H. Woo Et Al. , "Final analysis of phase 3 LATITUDE study in patients (pts) with newly diagnosed high-risk metastatic castration-naive prostate cancer (NDx-HR mCNPC) treated with abiraterone acetate plus prednisone (AA plus P) added to androgen deprivation therapy (ADT)," Annual Scientific Meeting of the Urological-Society-of-Australia-and-New-Zealand , vol.123, Brisbane, Australia, pp.27-28, 2019
Woo, H. Et Al. 2019. Final analysis of phase 3 LATITUDE study in patients (pts) with newly diagnosed high-risk metastatic castration-naive prostate cancer (NDx-HR mCNPC) treated with abiraterone acetate plus prednisone (AA plus P) added to androgen deprivation therapy (ADT). Annual Scientific Meeting of the Urological-Society-of-Australia-and-New-Zealand , (Brisbane, Australia), 27-28.
Woo, H., Fizaz, K., Sulur, G., Tran, N., Fein, L., Matsubara, N., ... Rodriguez-Antolin, A.(2019). Final analysis of phase 3 LATITUDE study in patients (pts) with newly diagnosed high-risk metastatic castration-naive prostate cancer (NDx-HR mCNPC) treated with abiraterone acetate plus prednisone (AA plus P) added to androgen deprivation therapy (ADT) . Annual Scientific Meeting of the Urological-Society-of-Australia-and-New-Zealand (pp.27-28). Brisbane, Australia
Woo, H. Et Al. "Final analysis of phase 3 LATITUDE study in patients (pts) with newly diagnosed high-risk metastatic castration-naive prostate cancer (NDx-HR mCNPC) treated with abiraterone acetate plus prednisone (AA plus P) added to androgen deprivation therapy (ADT)," Annual Scientific Meeting of the Urological-Society-of-Australia-and-New-Zealand, Brisbane, Australia, 2019
Woo, H. Et Al. "Final analysis of phase 3 LATITUDE study in patients (pts) with newly diagnosed high-risk metastatic castration-naive prostate cancer (NDx-HR mCNPC) treated with abiraterone acetate plus prednisone (AA plus P) added to androgen deprivation therapy (ADT)." Annual Scientific Meeting of the Urological-Society-of-Australia-and-New-Zealand , Brisbane, Australia, pp.27-28, 2019
Woo, H. Et Al. (2019) . "Final analysis of phase 3 LATITUDE study in patients (pts) with newly diagnosed high-risk metastatic castration-naive prostate cancer (NDx-HR mCNPC) treated with abiraterone acetate plus prednisone (AA plus P) added to androgen deprivation therapy (ADT)." Annual Scientific Meeting of the Urological-Society-of-Australia-and-New-Zealand , Brisbane, Australia, pp.27-28.
@conferencepaper{conferencepaper, author={H. Woo Et Al. }, title={Final analysis of phase 3 LATITUDE study in patients (pts) with newly diagnosed high-risk metastatic castration-naive prostate cancer (NDx-HR mCNPC) treated with abiraterone acetate plus prednisone (AA plus P) added to androgen deprivation therapy (ADT)}, congress name={Annual Scientific Meeting of the Urological-Society-of-Australia-and-New-Zealand}, city={Brisbane}, country={Australia}, year={2019}, pages={27-28} }